Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Follow-Up Questions
What is Viridian Therapeutics Inc (VRDN)'s P/E Ratio?
The P/E ratio of Viridian Therapeutics Inc is N/A
Who is the CEO of Viridian Therapeutics Inc?
Mr. Stephen Mahoney is the President of Viridian Therapeutics Inc, joining the firm since 2023.
What is the price performance of VRDN stock?
The current price of VRDN is 19.05, it has decreased 2.87% in the last trading day.
What are the primary business themes or industries for Viridian Therapeutics Inc?
Viridian Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Viridian Therapeutics Inc market cap?
Viridian Therapeutics Inc's current market cap is $1.5
Is Viridian Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 18 analysts have made analyst ratings for Viridian Therapeutics Inc, including 9 strong buy, 11 buy, 3 hold, 0 sell, and 9 strong sell
